Back to Journals » Biologics: Targets and Therapy » Volume 7

Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis

Authors Kaushik T, Yaqoob MM

Received 2 July 2013

Accepted for publication 13 September 2013

Published 11 November 2013 Volume 2013:7 Pages 243—246


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Tarun Kaushik, Muhammad Magdi Yaqoob

Barts Health NHS Trust, William Harvey Research Unit, London, UK

Abstract: Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration along with a possibly lower cost as a result of simpler manufacturing techniques compared with other available agents makes peginesatide a highly desirable product in the competitive ESA market. Peginesatide is noninferior to the other ESAs, and has a good safety profile in patients on hemodialysis. The higher rates of adverse cardiovascular events reported in CKD patients not on dialysis in the recent Phase III studies require further, better planned, studies. Peginesatide had to be withdrawn from the market in the US after some reports of hypersensitivity reactions to the drug. This is a setback, but the scientific advances gained as a result of this product development can be used to develop other, newer products.

Keywords: anemia, hemodialysis, chronic kidney disease, peginesatide

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.